Aplasia Treatment Market size is likely to register remarkable growth rate during the forecast period i.e., between 2024-2036. Aplasia is a rare genetic disorder, in which, major body parts or organs are either completely absent, or minimally present. This ranges from absence of blood cells, or lack of the ability to make new cells to absent limbs and internal organs. The lifespan of an aplasia patient ranges from a few weeks to a few years, depending on the fact that which body organ is not available. The growth of the market can be attributed to the increasing demand for treatment of aplasia, as there is no known cure for this disease. In addition to this, the increasing incidences of various genetic diseases, including all types of aplasia, are estimated to boost the market growth. According to the National Organization for Rare Disorders (NORD), in the United States approximately 500-1,000 new cases of aplastic anemia are diagnosed each year. On the other hand, the prevalence is 4-6 cases in a million in Asia, and 2-3 cases in a million in Europe.
Moreover, the growing medical R&D activities aiming to develop treatment drugs for rare diseases, along with the growing investment in the field of research, are projected to boost the aplasia treatment market growth. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
Regional Scope |
|
The market is segmented by type into germ-cell aplasia, radial aplasia, aplastic anemia, pure red cell aplasia, and others, out of which, the aplastic anemia segment is anticipated to hold the notable share in the global aplasia treatment market. This can be attributed to the higher prevalence of aplastic anemia, in which, the body stops generating new blood cells. The patient of aplastic anemia has a limited lifespan, which is estimated to boost the demand for treatment method extensively, which, in turn, is projected to fuel the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By End-User |
|
Regionally, the global aplasia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America industry is estimated to dominate majority revenue share by 2036, ascribed to growing healthcare expenditure, and increasing investment in medical research activities. According to the data by the World Bank, North America spent 2.734% of its GDP for R&D activities in 2018. The market in the Europe region is also estimated to gain notable share over the forecast period owing to the improving healthcare infrastructure, and growing awareness regarding rare diseases. Moreover, favorable government initiatives to promote medical research in countries, such as, Germany, Sweden, and Denmark, are estimated to promote the aplasia treatment market growth.
There is no known treatment available for aplasia, however, surgery and supportive therapy are used to treat the symptoms. Major pharmaceutical companies, such as,
February, 2021: Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio to production of antimicrobial drugs.
September, 2020: Mylan and Pfizer received approval from European Commission for consolidation of Mylan and Upjohn for distribution in Europe.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?